{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:28:56Z","timestamp":1761809336592,"version":"build-2065373602"},"reference-count":19,"publisher":"Wiley","issue":"20","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,10]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n \n Primary gastrointestinal (GI) diffuse large B\u2010cell lymphoma (DLBCL) is a rare malignancy. Given its rarity, the nature of the disease, particularly those originating in the colorectum, remains poorly defined.\n Aims:<\/jats:bold>\n This multicenter retrospective study analyzed the clinical characteristics and treatment outcomes of primary GI DLBCL, with a focus on colorectal cases.\n <\/jats:p>\n <\/jats:sec>\n \n Materials & Methods<\/jats:title>\n A total of 104 cases of primary GI DLBCL were retrospectively collected from three institutions (2010\u20132024) and classified into three groups based on the lymphoma's origin.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 104 patients, 57.7% had gastric, 18.3% small bowel, and 24.0% colorectal DLBCL. Approximately 60% presented with limited\u2010stage disease (Stage I\u2013II). All patients received front\u2010line R\u2010CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), achieving a complete remission (CR) rate of 81.0%. The estimated 3\u2010year overall survival (OS) and progression\u2010free survival (PFS) were 91.7% and 91.9%, respectively. Outcomes varied by disease origin, with gastric DLBCL showing the most favorable prognosis and small bowel the poorest (3\u2010year OS 93.9% vs. 69.3%).<\/jats:p>\n <\/jats:sec>\n \n Discussion<\/jats:title>\n \n In the colorectal subgroup (\n n<\/jats:italic>\n \u2009=\u200925), 84.0% had disease in the ascending colon, and 70.0% had limited\u2010stage disease. Obstructive symptoms were the most common initial presentation. The CR rate after R\u2010CHOP was 80.0%, with estimated 3\u2010year OS and PFS of 86.7% and 72.3%, respectively. While primary tumor resection improved local disease control, it did not confer an OS benefit. During follow\u2010up, 13.5% of patients experienced relapse, most frequently more than 12\u2009months after achieving CR. Relapsed or refractory primary GI DLBCL demonstrated better outcomes than conventional relapsed nodal DLBCL.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n These findings confirm the efficacy of front\u2010line R\u2010CHOP in primary GI DLBCL and suggest that primary tumor resection may be a useful component of treatment for localized primary colorectal DLBCL.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/cam4.71313","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:22:24Z","timestamp":1761070944000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Features and Outcomes of Primary Colorectal Diffuse Large B\u2010Cell Lymphoma: A Multicenter Retrospective Study"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6153-9742","authenticated-orcid":false,"given":"Yong\u2010Pyo","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Hematology\u2010Oncology, Department of Internal Medicine Chungbuk National University Hospital, Chungbuk National University College of Medicine Cheongju Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung\u2010Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine Chungnam National University Hospital, Chungnam National University College of Medicine Daejeon Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seonggyu","family":"Byeon","sequence":"additional","affiliation":[{"name":"Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine The Catholic University of Korea Seoul Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_9_2_1","DOI":"10.1023\/A:1008282818705"},{"doi-asserted-by":"publisher","key":"e_1_2_9_3_1","DOI":"10.1200\/JCO.1994.12.8.1673"},{"doi-asserted-by":"publisher","key":"e_1_2_9_4_1","DOI":"10.3748\/wjg.v17.i6.697"},{"doi-asserted-by":"publisher","key":"e_1_2_9_5_1","DOI":"10.4103\/0377-4929.91502"},{"doi-asserted-by":"publisher","key":"e_1_2_9_6_1","DOI":"10.3389\/fonc.2021.622648"},{"doi-asserted-by":"publisher","key":"e_1_2_9_7_1","DOI":"10.1111\/bjh.19470"},{"doi-asserted-by":"publisher","key":"e_1_2_9_8_1","DOI":"10.1182\/blood-2010-06-288480"},{"doi-asserted-by":"publisher","key":"e_1_2_9_9_1","DOI":"10.3389\/fonc.2024.1404298"},{"doi-asserted-by":"publisher","key":"e_1_2_9_10_1","DOI":"10.1002\/1097-0142(19800701)46:1<215::AID-CNCR2820460136>3.0.CO;2-6"},{"doi-asserted-by":"publisher","key":"e_1_2_9_11_1","DOI":"10.5045\/br.2022.2022037"},{"doi-asserted-by":"publisher","key":"e_1_2_9_12_1","DOI":"10.1182\/blood-2003-05-1545"},{"doi-asserted-by":"publisher","key":"e_1_2_9_13_1","DOI":"10.1093\/oxfordjournals.annonc.a058869"},{"doi-asserted-by":"publisher","key":"e_1_2_9_14_1","DOI":"10.1200\/JCO.2013.54.8800"},{"doi-asserted-by":"publisher","key":"e_1_2_9_15_1","DOI":"10.1200\/JCO.2001.19.18.3874"},{"doi-asserted-by":"publisher","key":"e_1_2_9_16_1","DOI":"10.1002\/cncr.11415"},{"doi-asserted-by":"publisher","key":"e_1_2_9_17_1","DOI":"10.1002\/cam4.3882"},{"doi-asserted-by":"publisher","key":"e_1_2_9_18_1","DOI":"10.1182\/blood.V110.11.3444.3444"},{"doi-asserted-by":"publisher","key":"e_1_2_9_19_1","DOI":"10.3346\/jkms.2014.29.1.53"},{"doi-asserted-by":"publisher","key":"e_1_2_9_20_1","DOI":"10.1093\/annonc\/mdj996"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:25:51Z","timestamp":1761809151000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":19,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/cam4.71313"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71313","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"type":"print","value":"2045-7634"},{"type":"electronic","value":"2045-7634"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-06-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71313"}}